Moon (Guangzhou) Biotech Co., Ltd, a leading microbiome platform company based in China, has reportedly secured RMB 300 million (USD 41.3 million) in a Series C+ financing round. The funding was exclusively provided by SDIC JULI Investment, a state-owned investment fund.
Established in 2015, Moon is recognized for possessing the world’s largest and most diverse collection of intestinal microbes, plant microbial species, and a gene bank. The company has discovered, preserved, and identified over 270,000 microbial strains with independent intellectual property rights. In the biomedicine sector, Moon’s pipeline includes three clinical-stage drugs and several pre-clinical candidates, addressing a range of conditions including oncology, obesity, type 2 diabetes, and nonalcoholic steatohepatitis.
The company’s tumor immunity drug, MNC-168, is currently in Phase I trials in China. Its metabolic disease drug, MNO-863, is noted as the first microbiome drug in China being developed for weight loss and metabolic syndrome applications. Moon has established partnerships with major pharmaceutical companies both domestically and internationally, including Novo Nordisk, Merck, and Hengrui Medicine. Additionally, the company has engaged in clinical collaborations with prominent medical institutions such as Guangdong Provincial People’s Hospital and PLA 301 Hospital.- Flcube.com
